We sought to provide clinicians and researchers with an inclusive view of IgE-mediated FA patients’ experiences, including (1) FA’s natural history, including signs, symptoms, health system experiences, and diagnosis pathways; (2) the disease’s burden and psychosocial impacts on individuals and families; (3) perspectives on treatment attributes, benefits, and clinical trial participation; and (4) topics and resources patients and caregivers seek regarding FAs. This evidence concerns the gene IGHE and Friedreich ataxia.